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Abstract
Background As is a prerequisite of belonging to the scavenger receptor super family, SCARF1 (scavenger receptor class F, 
member 1) is known to play a key role in the binding and endocytosis of a wide range of endogenous and exogenous ligands.
Findings Unlike most scavenger receptors, SCARF1 is an essential protein, as SCARF1-deficient mice exhibit a severe rest-
ing phenotype in which they develop systemic lupus erythematosus (SLE)-like disease, thus highlighting the importance of 
SCARF1-mediated clearance of apoptotic host cells in homeostasis. In addition, a number of other roles in homeostasis and 
disease pathology have also been suggested, including roles in both innate and adaptive immunity; however, the majority 
of these studies have utilised transfected cell lines engineered to ectopically express SCARF1 and very few have utilised 
in vivo or ex vivo approaches.
Conclusion This review summarises our current knowledge on SCARF1 biology and reflects on future directions for research 
on this multifaceted, yet largely understudied, scavenger receptor.
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Introduction
Scavenger receptors are a large super family of proteins 
which are defined by their ability to bind and endocytose a 
vast range of ligands, eliciting their ‘scavenging’ of unso-
licited endogenous and exogenous products [1]. Surpris-
ingly, ligand affinity is often shared by a number of scav-
enger receptors, despite the different classes (A–J) showing 
little or no structural homology [1, 2]. Scavenger receptor 
class F, member 1 (SCARF1 or SR-F1 [3]), also known as 
scavenger receptor expressed by endothelial cells (SREC-I), 
is an 86 kDa type I transmembrane protein which contains 
several epidermal growth factor (EGF)-like domains in its 
extracellular region, a short transmembrane domain, and a 
long, serine- and proline-rich cytoplasmic tail [4] (Fig. 1). 
SCARF1’s long cytoplasmic tail is highly unusual for a 
scavenger receptor and the only other scavenger with such an 
exaggerated intracellular domain is the SCARF1 homologue, 
and second member of the class F family, SCARF2 [5]. The 
length of their cytoplasmic domains is highly suggestive of 
a role in intracellular signaling; however, this function is yet 
to be elucidated. SCARF1 is a highly evolutionarily con-
served scavenger receptor, as its extracellular domain shows 
a significant sequence homology with the Caenorhabditis 
elegans scavenger receptor, CED-1 [6], a receptor which 
plays a key role in the homeostasis and innate immunity 
of C. elegans [6, 7]. Its homology with such a key protein 
in C. elegans is highly suggestive of an important role for 
SCARF1 in mammalian biology and, unlike the majority 
of scavenger receptor-deficient mouse lines which do not 
exhibit a resting state phenotype, the importance of SCARF1 
becomes apparent in SCARF1-deficient  (SCARF1−/−) mice 
which spontaneously develop systemic lupus erythematosus 
(SLE)-like autoimmune disease from 20 weeks of age. This 
autoimmune disease phenotype results from a significantly 
impaired clearance of apoptotic cells from key immunologi-
cal organs, such as the spleen, and manifests in SLE-like 
symptoms, such as increased production of autoantibodies, 
splenomegaly and larger germinal centres with increased 
 CD4+ T cells and B cells, severe dermatitis, and nephritis 
[8].
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SCARF1 was first cloned from human umbilical vein 
endothelial cells (HUVEC) [4], but has since been shown to 
be expressed in a number of different cell types, including 
sinusoidal endothelial cells [9, 10], dendritic cells [8, 11], 
macrophages [8, 10], epithelial cells [12, 13], and B-1 cells 
[8]. However, the majority of studies exploring SCARF1 
functionality have utilised transfected cell lines engineered 
to ectopically express the scavenger in vitro and very few 
have used primary cells which naturally express SCARF1 or 
in vivo approaches. In addition, the early studies on SCARF1 
showed high transcriptional expression in a wide range of 
major human tissues, such as heart, kidney, liver, lung, and 
spleen [5], and this was later corroborated in murine tissues 
[8, 14]; however, there has been a distinct lack of studies 
exploring its expression and cellular distribution at the pro-
tein level in these tissues. Indeed, to date, there has only 
recently been one study which has thoroughly characterised 
the expression and cellular distribution of SCARF1 in both 
normal and chronically diseased human liver tissues [10]; 
therefore, there is currently a huge void in our knowledge of 
SCARF1 biology in human tissues and cells.
Soluble SCARF1
Many scavenger receptors are known to exist in general cir-
culation in a soluble form, which is often released via cell 
surface cleavage by exofacial proteases [1], and SCARF1 
is no exception as it was recently shown for the first time 
that a truncated (~ 60 kDa) soluble form (sSCARF1) is the 
major species detectable in human serum [10]. Interestingly, 
the sSCARF1 was also detected in chronically diseased 
human liver tissues, but was absent from normal tissues; 
it was speculated that normal tissues did not contain the 
unknown protease(s) which were responsible for the cleav-
age of SCARF1 [10]. The functions of soluble scavenger 
receptors remain largely unknown, but their levels are often 
regulated in correlate with the extent of disease and so some, 
such as CD36 and CD163, exhibit the potential to become 
biomarkers [15, 16]; nevertheless, sSCARF1 did not seem 
to be regulated in chronic liver disease patients compared to 
normal controls [10]. Nevertheless, it would be interesting 
to explore serum levels of sSCARF1 in a range of patient 
cohorts with other inflammatory diseases known to involve 
scavenger receptors, such as atherosclerosis or Alzheimer’s 
disease, to further investigate its potential as a biomarker.
Functions of SCARF1
As is a prerequisite of scavenger receptor classification, 
SCARF1 is a highly promiscuous receptor and has been 
shown to bind a wide range of endogenous and exogenous 
ligands (Table 1). The functions of SCARF1 in relation to 
these ligands are discussed below.
Low‑density lipoprotein (LDL) binding
The first scavenger receptor was described in the late 1970s 
by Brown and Goldstein, and was defined by its ability to 
bind and subsequently internalise low-density lipoproteins 
(LDLs) [28, 29]; therefore, upon identification of a potential 
new scavenger receptor, its ability to bind LDLs is often 
Fig. 1  Diagrammatic repre-
sentation of the structure of 
SCARF1. SCARF1 is a type I 
transmembrane protein consist-
ing of three major domains: 
(1) an N-terminal extracellular 
region comprising of several 
epidermal growth factor (EGF)-
like domains (blue diamonds); 
(2) a short transmembrane 
domain (pink rectangle) which 
spans the phospholipid bilayer 
(represented by the yellow ovals 
and ‘S’-shaped curves) of the 
host cell; and (3) a relatively 
long cytoplasmic and C-termi-
nal tail region (red oval), which 
is rich in serine and proline 
residues. ‘N’ is representative 
of the amino (N)-terminus and 
‘C’ represents the carboxyl (C)-
terminus. (Color figure online)
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the first test to be undertaken. Consequently, in the origi-
nal paper in which SCARF1 was cloned, they demonstrated 
its binding ability to modified LDLs, including acetylated 
(Ac-) and oxidized (ox)LDLs [4]. Subsequently, SCARF1 
has also been shown to bind to carbamylated (c)LDLs [30]. 
As a result of their function as LDL receptors, a number of 
scavenger receptors, such as CD36 and LOX-1, are known to 
play an important role in the pathophysiology of atheroscle-
rosis [31–33]; however, the contribution of SCARF1 to this 
inflammatory cardiovascular disease has yet to be explored 
in any capacity.
Apoptotic cell clearance
Given that more than  109 cells undergo apoptosis in the 
human body per day, a rapid and immunologically ‘clean’ 
removal of apoptotic cells by neighbouring phagocytic cells 
is essential for the maintenance of homeostasis and avoid-
ance of inflammation [34]. The first indications of SCARF1’s 
involvement in this vital homeostatic process were the early 
findings of Berwin and colleagues who demonstrated its 
binding interaction with calreticulin [20], an important 
chaperone protein heavily implicated in the active uptake of 
apoptotic cells [35]. Following this, a seminal study by Ram-
irez-Ortiz et al. demonstrated that  SCARF1−/− mice sponta-
neously develop SLE-like autoimmune disease at 20 weeks 
of age as a consequence of impaired apoptotic cell clear-
ance, thus highlighting the prominence of SCARF1 in this 
homeostatic process [8]. Their study elegantly demonstrated 
that SCARF1-expressing splenic dendritic cells, sinusoidal 
endothelial cells, and macrophages all significantly contrib-
uted to the clearance of apoptotic cells through binding to 
the complement factor, C1q [8], which, in turn, binds to the 
‘eat-me’ signal, phosphatidylserine, presented on the surface 
of cells undergoing the early stages of apoptosis [36]. Nev-
ertheless, this study was undertaken in the relatively artifi-
cial context of transgenic mice completely lacking SCARF1 
expression in all tissues and so its translational relevance to 
the human disease still remains to be seen.
Innate immunity
SCARF1 has been shown to bind a diverse range of bac-
terial (both Gram-positive and Gram-negative), viral, and 
fungal antigens (Table 1), thus implicating it in host innate 
immunity; however, whether its role is beneficial or detri-
mental is still relatively unclear. Two studies have implicated 
SCARF1 in adherence of bacteria on epithelial tissues and 
have suggested that the bacteria may utilise the scavenger 
receptor to promote their dissemination from the primary 
infection site to systemic circulation and distal tissues. One 
of these studies identified epithelial-expressed SCARF1 as 
a highly selective receptor for the Neisseria gonorrhoeae 
porin protein, PorBIA, in in vitro bacterial adhesion assays 
[13], whilst the other elegantly showed, both in vitro and 
in vivo, that Staphylococcus aureus is able to avidly bind 
SCARF1 expressed on nasal epithelial cells via its wall 
teichoic acid (WTA) [12]. However, although these studies 
showed that antibody blockade of SCARF1 on the epithelial 
layers effectively prevented adhesion of their respective bac-
terial strains, their conclusions that SCARF1 may promote 
bacterial invasion may be unfounded, as they both failed to 
consider the bacteria–SCARF1 interaction from a host per-
spective. Epithelial tissues are well characterised to evoke 
effective and efficient host immunological responses when 
under pathogenic attack [37, 38], yet neither study explored 
the SCARF1-mediated stimulation of the epithelial tissues, 
which could potentially facilitate these host responses.
It has also been suggested that SCARF1 could play an 
indirect role in the capture and uptake of bacteria via two 
homologous endogenous ligands, the Tamm–Horsfall pro-
tein (THP) [21] and pancreatic zymogen granule protein 2 
(GP2) [22]. Although the physiological functions of THP 
Table 1  Known SCARF1 ligands
A number of endogenous and exogenous ligands have been described 
in the literature to date and are listed above
S. aureus: Staphylococcus aureus, K. pneumonia: Klebsiella pneumo-
nia, N. gonorrhoeae: Neisseria gonorrhoeae, C. albicans: Candida 
albicans, C. neoformans: Cryptococcus neoformans
Ligand References
Endogenous
 SCARF1 [5]
 SCARF2 [5]
 Modified low-density lipoproteins (oxLDLs and 
AcLDLs)
[4]
 Apoptotic cells (via complement factor C1q) [8]
 Heat shock proteins (Hsp70, Hsp90, Hsp110) [11, 17–19]
 Calreticulin [20]
 Tamm–Horsfall protein [21]
 Pancreatic zymogen granule protein 2 (GP2) [22]
 Protein phosphatase 1α
CD4+ T cells (unknown ligand)
[23]
[10]
Exogenous
 Bacterial antigens
  Teichoic acid (S. aureus) [12]
  Lipopolysaccharide (LPS) [10, 24]
  Outer membrane protein (Omp)A (K. pneumoniae) [25]
  Porin (Por)BIA (N. gonorrhoeae; via Gp96) [13]
 Viral antigens
  Non-structural protein (NS)3 (Hepatitis C virus; 
HCV)
[26]
  dsRNA [27]
 Fungal antigens
  β-Glucan (C. albicans and C. neoformans) [6]
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and GP2 are yet to be elucidated, both have been shown 
to directly bind bacteria in vitro and could, therefore, act 
as opsonising or bridging agents which then bind SCARF1 
on nearby immune cells and mediate the relevant immuno-
logical response; however, this is purely speculation on the 
author’s part and clearly further research is required.
In addition, a number of studies have shown evidence to 
suggest that SCARF1 acts in cooperation with a family of 
essential pattern recognition receptors (PRRs), called the 
Toll-like receptors (TLRs), to bind a range of pathogen-
associated molecular patterns (PAMPs) and elicit a proin-
flammatory immunological response. A study by Jeannin et 
al. demonstrated that SCARF1 was able to directly bind an 
outer membrane protein (OmpA) isolated from Klebsiella 
pneumonia, but required the presence of TLR2 to elicit the 
release of the potent neutrophil chemoattractant and proin-
flammatory cytokine, IL-8, from transfected Chinese ham-
ster ovarian (CHO) cells [25]. A seminal study by Means 
and colleagues also demonstrated in vitro and in vivo that 
SCARF1 is able to mediate binding and uptake of the fungal 
pathogens, Cryptococcus neoformans and Candida albicans, 
via β-glucan, but, again, the presence of TLR2 was required 
to elicit macrophage activation and the initiation of a proin-
flammatory immune response [6]. Furthermore, it has also 
been shown that SCARF1 again cooperates with TLR2 to 
induce myeloid cell activation in response to the hepatitis 
C virus (HCV) protease, non-structural protein (NS)3 [26]. 
More recently, Murshid and colleagues have also shown that 
the presence of SCARF1 can augment the TLR-mediated 
activation of the NF-κB pathway and ultimately the release 
of proinflammatory cytokines, such as IL-8, IL-6, and 
TNFα, in cells stimulated with either the TLR3 ligand, poly 
I:C (dsRNA) [27], or the TLR4 ligand, lipopolysaccharide 
(LPS) [24].
As mentioned previously, much of this work has utilised 
in vitro experimentation in cell lines ectopically expressing 
SCARF1; and, although these results are promising, their 
validation in primary cells which naturally express SCARF1, 
in more sophisticated multi-cellular in vitro models (e.g., 
organoids), or in murine models of infection is required to 
fully appreciate the role of SCARF1 in the innate immunity.
Adaptive immunity
In addition to being implicated in the innate immunity, there 
is evidence to suggest that SCARF1 is also involved in the 
adaptive immunity and facilitates the uptake of chaperone-
bound antigens and their subsequent antigen presentation to 
T cells [11, 17–19]. These studies have demonstrated that 
SCARF1 expressed on antigen presenting cells (APCs), such 
as dendritic cells, is able to internalise heat shock protein 
(Hsp)-bound antigens and load them, through the endosomal 
network, onto the cross presentation (MHC class I-mediated) 
[19] or class II presentation (MHC class II-mediated) [11, 
17] pathway and subsequently active the adaptive immunity. 
Indeed, these studies went on to show that SCARF1-medi-
ated presentation of Hsp-bound antigens on APCs was able 
to prime the activation of  CD8+ or  CD4+ T cells [11, 17, 19], 
dependent on the presentation pathway followed. However, 
it is currently unclear as to whether the choice in presenta-
tion pathway is purely stochastic in nature or if it is an active 
‘choice’ by the APC mediated in some way by SCARF1 and 
future studies should consider this phenomenon.
Leukocyte adhesion molecule
The leukocyte adhesion cascade is a multi-step process 
which facilitates the extravasation of leukocytes from cir-
culation into inflamed tissues during injury or infection, 
with the primary aim of eliminating the inflammatory 
trigger and/or contributing to tissue repair. The adhesion 
cascade is mediated by a large number of chemoattractant 
cytokines (chemokines) [39] and adhesion molecules [40], 
and several endothelial-expressed scavenger receptors, such 
as stabilin-1 and lectin-like oxidized low-density lipoprotein 
receptor-1 (LOX-1), have previously been shown to directly 
bind leukocytes and facilitate their recruitment to various 
vascular endothelia [41–47]. An early study demonstrated 
that SCARF1-expressing cells can form moderate homo-
philic cell–cell interactions with each other and strong het-
erophilic interactions with SCARF2-expressing cells [5], an 
effect which implied the potential for SCARF1 to also medi-
ate leukocyte recruitment. Recently, my lab characterised 
SCARF1 expression in primary human hepatic sinusoidal 
endothelial cells (HSEC) and, utilising a combination of 
recombinant proteins, HSEC and siRNA knockdowns in 
HSEC, we were able to robustly demonstrate that SCARF1 
plays a role in the selective recruitment of  CD4+ T cells to 
the sinusoidal endothelium under physiological shear stress 
conditions [10]. In this study, we proposed that SCARF1 
acts in the firm adhesion step of the leukocyte adhesion cas-
cade, showing  SCARF1+ adhesive cups form on the surface 
of the HSEC [10]; however, we did not explore the possibil-
ity SCARF1’s involvement in the transendothelial migration 
step of the cascade and future investigations will explore 
this. We also ruled out the possibility that this SCARF1-
lymphocyte binding is mediated through homophilic inter-
actions with itself or through heterophilic interactions with 
its homologue, as  CD4+ T cells do not express SCARF1 
[10] or SCARF2 (unpublished data). Therefore, the lym-
phocyte-expressed ligand of SCARF1 is yet to be identified 
and screening experiments could be employed to determine 
this in future investigations. Furthermore, our demonstration 
of SCARF1’s adhesive function has only been in in vitro 
systems and so future studies will also aim to validate this 
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in vivo, utilising a combination of liver injury models and 
intravital imaging in  SCARF1−/− mice.
Conclusions
SCARF1 is known to bind a wide range of ligands both 
endogenous and exogenous in nature; consequently, a num-
ber of biological roles in homeostasis, immunity, and dis-
ease pathology have previously been suggested. However, 
the majority of studies undertaken thus far have relied heav-
ily on in vitro experiments involving the ectopic expression 
of SCARF1 in cell lines and, whilst the validity and value 
of these studies is not being called into question here, this 
review highlights the distinct lack of research with regards 
to SCARF1 which utilises naturally expressing primary cells 
and ex vivo or in vivo approaches. Consequently, the cellular 
and tissue expression and function of this highly promis-
cuous scavenger receptor still remain a mystery and future 
studies should aim to reduce this significant deficit.
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